Data from anti-PD-1 monotherapy studies (3336 patients with nivolumab and 3301 patients with pembrolizumab) are in keeping with a greater incidence of myositis (2.6% for nivolumab and 1.07% for pembrolizumab) than of peripheral neuropathy (0.73% and 0.28%, respectively) [9]. Here, PDCD1 is linked to myositis disease.